Utilidad de la buprenorfina transdérmica en el manejo del dolor oncológico ION SOLCA Dr. Juan Tanca Marengo 2010-2012
Fecha
2015
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
El tratamiento del dolor oncológico es un tema cuyo abordaje debe comprometer a todo el equipo de salud en la atención de los pacientes. Es una entidad a la que los anestesiólogos se enfrentan a diario, debido a que el manejo es complejo porque el dolor es una sensación subjetiva, que varía de sujeto a sujeto y no es posible cuantificarlo con exactitud. El propósito del estudio fue demostrar la eficacia y seguridad del empleo de la buprenorfina TD (BNTD) en el tratamiento del dolor moderado y severo en pacientes oncológicos. La población constituida por los pacientes de cuidados paliativos del ION SOLCA 2010 - 2012 la muestra no probabilística. La investigación fue de tipo descriptiva y diseño no experimental – transversal. La recolección de datos se llevará a cabo mediante el método de fuentes documentales. Las principales conclusiones fueron: La buprenorfina transdérmica se adaptó a las necesidades individuales de intensidad del dolor, utilizándose la dosis más baja posible para conseguir el alivio del dolor. La primera evaluación del efecto analgésico de la BNTD se realizó después de las primeras 36 horas, ajustando la dosis individualmente hasta alcanzar la eficacia analgésica y cuando la analgesia no fue suficiente se aumentó la dosis para aumentar la concentración. El riesgo de dependencia es bajo, debido al perfil del principio activo buprenorfina y la forma de aplicación transdérmica.Se puede aprovechar la posibilidad de cortar el parche para ajustar la dosis a las necesidades individuales de cada paciente. La buprenorfina es eficaz y segura en el manejo de dolor oncológico crónico, con menor presencia de efectos colaterales. Es de fácil aplicación (dos cambios por semana) y adecuada tolerancia, se convierte en una alternativa con alta comodidad para el paciente, al facilitar el cumplimiento de la terapéutica en los pacientes oncológicos con dolor crónico
The treatment of cancer pain is an issue which approach should involve the whole health team in the care of patients. Anesthesiologists face an entity daily, because the management is complex because pain is a subjective sensation, which varies from subject to subject and it is not possible to quantify accurately. The purpose of the study was to demonstrate the efficacy and safety of the use of TD (BNTD) buprenorphine in the treatment of moderate to severe cancer pain. The population comprised patient’s hospice SOLCA ION 2010 – 2012 non-probability sample. The research was descriptive and nonexperimental design - cross. Data collection was conducted by the method of documentary sources. The main findings were: Transdermal buprenorphine was adapted to the individual needs of pain intensity, the lowest possible dose used to achieve pain relief. The first evaluation of the analgesic effect of BNTD was performed after 36 hours, individually adjusting the dose reaching the analgesic efficacy and when analgesia was not enough the dose was increased to increase the concentration. The risk of dependence is low, due to the profile of the active ingredient buprenorphine and application form transdérmica, can use the possibility to cut the patch to adjust the dose to the individual needs of each patient. Buprenorphine is effective and safe in the management of chronic cancer pain, with lower incidence of side effects. It is easy to apply (two changes per week) and adequate tolerance becomes an alternative high comfort for the patient, to facilitate compliance with therapy in cancer patients with chronic pain.
The treatment of cancer pain is an issue which approach should involve the whole health team in the care of patients. Anesthesiologists face an entity daily, because the management is complex because pain is a subjective sensation, which varies from subject to subject and it is not possible to quantify accurately. The purpose of the study was to demonstrate the efficacy and safety of the use of TD (BNTD) buprenorphine in the treatment of moderate to severe cancer pain. The population comprised patient’s hospice SOLCA ION 2010 – 2012 non-probability sample. The research was descriptive and nonexperimental design - cross. Data collection was conducted by the method of documentary sources. The main findings were: Transdermal buprenorphine was adapted to the individual needs of pain intensity, the lowest possible dose used to achieve pain relief. The first evaluation of the analgesic effect of BNTD was performed after 36 hours, individually adjusting the dose reaching the analgesic efficacy and when analgesia was not enough the dose was increased to increase the concentration. The risk of dependence is low, due to the profile of the active ingredient buprenorphine and application form transdérmica, can use the possibility to cut the patch to adjust the dose to the individual needs of each patient. Buprenorphine is effective and safe in the management of chronic cancer pain, with lower incidence of side effects. It is easy to apply (two changes per week) and adequate tolerance becomes an alternative high comfort for the patient, to facilitate compliance with therapy in cancer patients with chronic pain.
Descripción
PDF
Palabras clave
Buprenorfina, Dolor, Oncología médica, Parche transdérmico, Cuidados paliativos, Epidemiología descriptiva, Hospital SOLCA de Guayaquil, Cantón Guayaquil, Ecuador